G. B. Preethi, H. N. Shivakumar, M Ravi Kumar, N Sweta


Objective Lipid-based formulations have gained much attention particularly on Self-Emulsifying Drug Delivery Systems (SEDDS), to improve the oral bioavailability of lipophilic drugs. In the present study an attempt was made to develop and evaluate prototype SEDDS of poorly soluble antiviral BCS class IV drug Etravirine.

Methods Various oils, surfactants and co-surfactants were screened for their suitability in the formulation of SEDDS. Based on the screening, Gelucire 44/14, as the Oil, Labrasol as surfactant and Transcutol HP as the co-surfactant were selected. SEDDS with drug etravirine was formulated and evaluated for emulsifying ability, dilution potential and were found to be satisfactory. The emulsion area for each of the combination of Oil and Smix was determined by the construction of pseudo ternary phase diagrams.

Results Based on the studies, Oil(Gelucire 44/14) and Smix(Labrasol:Transcutol HP, 6:1) in a ratio of 2:8 was selected and evaluated for parameters like drug content, percentage transmittance, dilution potential, emulsification time and was found to be optimized formulation. The optimized formulation exhibited a rapid emulsification rate and a good polydispersibility index of 0.103 ±0.012 indicating uniformity of the formed droplets. The size of the droplets was determined by Zetasizer and was found to be in 200 nm range. The percentage drug release from the final formulation was improved compared to that of pure drug indicating good solubilization of the drug.



Etravirine, Self emulsifying system, Gelucire44/14, BCS class IV, Antiretroviral



Elizabeth O, Irene M, Panjasaram N, Thirumala G. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm. 2008;70: 697–710.

Archita P, Anita L. Self microemulsifying drug delivery system as a potential drug delivery system for protease inhibitors in the treatment of AIDS. Asian J Pharm. 2011;6 (5): 226-240.

Umesh G, Narendra KJ. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Deliv Rev. 2010;62:478-90.

Marie-PB. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009). Antiviral Res. 2010; 85; 75–90.

Schiller DS, Youssef-Bessler M. Etravirine: A Second-Generation Non-nucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-Resistant Strains of HIV. Clin Ther. 2009; 31(4); 692-704.

Jessica A, Nimish P, Nancy, Mariam T, and Christopher DM. Nonnucleoside Reverse Transcriptase Inhibitor Resistance and the Role of the Second-Generation Agents. Ann Pharmacother. 2010; 44 (1):157-65.

Leonard B. Johnson and Louis D. Saravolatz. Etravirine, a Next-Generation Non-nucleoside Reverse-Transcriptase Inhibitor. Clin Infect Dis. 2009; 48(8):1123-8.

Yohei K, Koichi W, Manabu N, Shizuo Y, Satomi O. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int. J. Pharm. 2011; 420 (1):1– 10.

Sandeep K, Mohanvarma M,Veerabhadhraswamy P. Oral lipid-based drug delivery systems – an overview. Acta PharmaceuticaSinicaB. 2013;3(6):361–72.

Colin W. Pouton. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J Pharm Sci. 2000 ;( 11 Suppl. 2);S93–S98.

Christopher JH Porter, Colin WP, Jean F. Cuine, William NC. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Deliv. Rev. 2008; 60 (6). 673–91.

Jaime AY, Stephen WJ. Wang, Ian WK, Mark AW, Kevin BA. Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev. 201;163 (10-11):923–42.

Anne C, Thomas B, Werner W. Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes. Eur J Pharm Sci. 2010; 41 (2):376–82.

Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm. 2000;50(1):179-88.

Mohd JQ, Chitneni M, Wong GK. Enhancement of solubility and therapeutic potential of poorly soluble lovastatin by SMEDDS formulation adsorbed on directly compressed spray dried magnesium aluminometasilicate liquid loadable tablets: A study in diet induced hyperlipidemic rabbits. Asian J. Pharm. 2015;10 (1):40–56.

Naser M.Y. Hasan. Role of medium-chain fatty acids in the emulsification mechanistics of self-micro-emulsifying lipid formulations. Saudi Pharm J. 2014;22(6):580–90.

R. Neslihan Gursoy , Simon B. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 2004;58 (3) 173–182.

Zupančič O, Grieβinger JA, Rohrer J, Pereira de Sousa I, Danninger L, Partenhauser A, Sündermann NE, Laffleur F, Bernkop-Schnürch A. Development. In vitro and in vivo evaluation of a self-emulsifying drug delivery system (SEDDS) for oral enoxaparin administration. Eur J Pharm Biopharm. 2016;109:113-21.

Huiyi W, Xiaoying L, FeiYuana, Li C, Sujing P, Yunjun L, Yoshiko S, Xiaoling L. Combined use of phospholipid complexes and self-emulsifying microemulsions for improving the oral absorption of a BCS class IV compound, baicalin. Acta Pharm Sin B. 2014; 4(3):217–26.

Shweta G, Sandip C, Krutika KS. Self-nanoemulsifying drug delivery system for adefovir dipivoxil: Design, characterization, in vitro and ex vivo evaluation. Colloids Surf A Physicochem Eng Asp . 2011; 392 (1):145– 55.

Prajapati HN, Dalrymple DM, Serajuddin AT. A Comparative Evaluation of Mono-, Di- and Triglyceride of Medium Chain Fatty Acids by Lipid/Surfactant/Water Phase Diagram, Solubility Determination and Dispersion Testing for Application in Pharmaceutical Dosage Form Development. Pharm Res. 2012;29(1):285-305.

Prakash CS. Sunit K S, Alakh NS. Mixed surfactant based (SNEDDS) self-nanoemulsifying drug delivery system presenting efavirenz for enhancement of oral bioavailability. ‎Biomed. Pharmacother . 2016;80: 42–51.

Kotta S, Khan AW, Ansari SH, Sharma RK, Ali J. Anti HIV nanoemulsion formulation: Optimization and in vitro–in vivo evaluation. Int J Pharm. 2014; 462(1-2):129-34.

Shubham R, Mohd Y. Cinnarizine loaded lipid based system: preparation,optimization and in –vitro evaluation. Journal of Pharmacy. 2012; 2 (5) 47-56.

Meena AK1, Sharma K, Kandaswamy M, Rajagopal S, Mullangi R.. Formulation development of an albendazole self-emulsifying drug delivery system (SEDDS) with enhanced systemic exposure. Acta Pharm. 2012; 62(4):563-80.

Amit AK and Vandana BP. Design and Evaluation of Self-Emulsifying Drug Delivery Systems (SEDDS) of Nimodipine. AAPS PharmSciTech. 2008; 9 (1) 191–96.

Patel D Sawant KK. Oral Bioavailability Enhancement of Acyclovir by Self-Microemulsifying Drug Delivery Systems (SMEDDS). Drug Dev Ind Pharm. 200; 33(12):1318-26.

Soliman MS, Khan MA. Preparation and in vitro characterization of a semi-solid dispersion of flurbiprofen with Gelucire 44/14 and Labrasol. Pharmazie. 2005;60(4):288-93.

Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev. 2008; 60(6):734-46.

Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm. 2000;50(1):179-88.

Syed HK, Peh KK.. Identification of phases of various oil, surfactant/co-surfactants and water system by ternary phase diagram. Acta Pol Pharm. 2014;71(2):301-9.

Venkata RK, Basanth BE, Raju J, Ram KA, Suresh B. A Gelucire 44/14 and labrasol based solid self emulsifying drug delivery system: formulation and evaluation. J Pharm Investig. 2013, 43(3).185–96.

Yüksel N, Karataş A, Ozkan Y, Savaşer A, Ozkan SA, Baykara T. Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2003;56(3):453-9.

Koga K, Kusawake Y, Ito Y, Sugioka N, Shibata N, Takada K.. Enhancing mechanism of Labrasol on intestinal membrane permeability of the hydrophilic drug gentamicin sulfate. Eur J Pharm Biopharm. 2006;64(1):82-91.

Prasad YV, Puthli SP, Eaimtrakarn S, Ishida M, Yoshikawa Y, Shibata N, Takada K.. Enhanced intestinal absorption of vancomycin with Labrasol and D-a-tocopheryl PEG 1000 succinate in rats. Int J Pharm. 2003;250(1):181-90.

Delongeas JL, de Conchard GV, Beamonte A, Bertheux H, Spire C, Maisonneuve C, Becourt-Lhote N, Goldfain-Blanc F, Claude N.. Assessment of Labrasol_/Labrafil_/Transcutol_ (4/4/2, v/v/v) as a non-clinical vehicle for poorly water-soluble compounds after 4-week oral toxicity study in Wistar rats. Regul Toxicol Pharmacol. 2010; 57(2-3):284-90.

Mura P, Faucci MT, Bramanti G, Corti P. Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur J Pharm Sci. 2000 Feb; 9(4):365-72..

Mahmoud DB, Shukr MH, Bendas ER. In vitro and in vivo evaluation of self-nanoemulsifying drug delivery systems of cilostazol for oral and parenteral administration. Int J Pharm. 2014 Dec 10; 476(1-2):60-9.

Lee DH, Yeom DW, Song YS, Cho HR, Choi YS, Kang MJ, Choi YW. Improved oral absorption of dutasteride via Soluplus1-based supersaturable self-emulsifying drug delivery system (S-SEDDS). Int J Pharm. 2015 Jan 15; 478(1):341-7.

Nahla SB. Enhanced oral bioavailability of etodolac by self-emulsifying systems: in-vitro and in-vivo evaluation. Journal of Pharmacy and Pharmacology 2010; 62: 173–180.

Jaydeep P, Anjali P, Mihir R, and Navin S. Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan. J Adv Pharm Technol Res. 2011 Jan-Mar; 2(1): 9–16.

Fatal error: Call to a member function getGalleyLabel() on null in /home/innowar1/public_html/journals/cache/t_compile/%%38^38D^38D7420B%%article.tpl.php on line 189